Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 11, 2025
- Accession no.
- 0001447362-25-000042
- Filed
- Mar 11, 2025
- Trade date
- Mar 7-10, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 15 non-derivative transactions. Open-market sales total $585.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2025 | Common Stock | SSaleDisposed | −20,516 | $20.05F2 | −$411,345.8 | 82,588 | Direct | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −1,828 | $20.05F2 | −$36,651.4 | 67,231 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −1,569 | $20.05F2 | −$31,458.45 | 57,265 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −150 | $20.05F2 | −$3,007.5 | 4,788 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −150 | $20.05F2 | −$3,007.5 | 4,785 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −150 | $20.05F2 | −$3,007.5 | 4,785 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −150 | $20.05F2 | −$3,007.5 | 4,785 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −2,123 | $20.74F9 | −$44,031.02 | 80,465 | Direct | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −189 | $20.74F9 | −$3,919.86 | 67,042 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −162 | $20.74F9 | −$3,359.88 | 57,103 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −15 | $20.74F9 | −$311.1 | 4,773 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −15 | $20.74F9 | −$311.1 | 4,770 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −15 | $20.74F9 | −$311.1 | 4,770 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −15 | $20.74F9 | −$311.1 | 4,770 | Indirect | |
| Mar 10, 2025 | Common Stock | SSaleDisposed | −2,130 | $19.52F10 | −$41,577.6 | 78,335 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $19.560 to $20.550, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $20.570 to $20.915, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $19.350 to $19.790, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.